作者
Laurent Bonello, Udaya S Tantry, Rossella Marcucci, Ruediger Blindt, Dominick J Angiolillo, Richard Becker, Deepak L Bhatt, Marco Cattaneo, Jean Philippe Collet, Thomas Cuisset, Christian Gachet, Gilles Montalescot, Lisa K Jennings, Dean Kereiakes, Dirk Sibbing, Dietmar Trenk, Jochem W Van Werkum, Franck Paganelli, Matthew J Price, Ron Waksman, Paul A Gurbel, Working Group on High On-Treatment Platelet Reactivity
发表日期
2010/9/14
来源
Journal of the American College of Cardiology
卷号
56
期号
12
页码范围
919-933
出版商
American College of Cardiology Foundation
简介
The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of patients with cardiovascular disease. However, recurrent ischemic event occurrence during dual antiplatelet therapy, including stent thrombosis, remains a major concern. Platelet function measurements during clopidogrel treatment demonstrated a variable and overall modest level of P2Y12inhibition. High on-treatment platelet reactivity to adenosine diphosphate (ADP) was observed in selected patients. Multiple studies have now demonstrated a clear association between high on-treatment platelet reactivity to ADP measured by multiple methods and adverse clinical event occurrence. However, the routine measurement of platelet reactivity has not been widely implemented and recommended in the guidelines. Reasons for the latter include: 1) a lack of consensus on the optimal method to quantify high on-treatment platelet …
引用总数
201020112012201320142015201620172018201920202021202220232024121352171911731391247965497255422815